Dr. Agarwal's Health Care Q2 FY27: Revenue ₹655 Cr (+31.4%), PAT ₹57 Cr (+55.8%)
Dr. Agarwal's Health Care reported Q2 FY27 revenue of ₹655 Cr (up 31.4% YoY) and PAT of ₹57 Cr (up 55.8% YoY). For H1 FY27, revenue was ₹1,269 Cr (up 28.7% YoY) and PAT was ₹112 Cr (up 50.1% YoY). Dr. Amar Agarwal was appointed Executive Chairman.
The strong financial performance, coupled with a significant management change, is likely to have a considerable impact on investor sentiment and the company's future trajectory. The expansion of facilities and clinical innovation also contribute to the high impact.
The company has reported strong year-on-year growth in revenue, EBITDA, and PAT for both the quarter and half-year. The appointment of a key management personnel also adds to the positive outlook.
Dr. Agarwal's Health Care Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. For the quarter (Q2 FY27), Revenue from Operations grew by 31.4% year-on-year to ₹655 Crores, and Profit After Tax (PAT) surged by 55.8% to ₹57 Crores. EBITDA for the quarter was ₹186 Crores, a 28.8% increase year-on-year.
For the half-year (H1 FY27), Revenue from Operations increased by 28.7% year-on-year to ₹1,269 Crores, and PAT grew by 50.1% to ₹112 Crores. EBITDA for the half-year stood at ₹362 Crores, up 27.0% year-on-year.
The company also announced the appointment and re-designation of Dr. Amar Agarwal as the Executive Chairman (Whole-Time Director) for a period of three years, effective November 01, 2026. This appointment is subject to shareholder approval via a postal ballot process.
Dr. Adil Agarwal, CEO, highlighted strong growth across key metrics, with Q2 being the highest-ever quarter. The company expanded its network to 324 facilities and performed 186,923 surgeries in H1 FY27. A significant clinical development mentioned is the opening of the world's first dedicated Pinhole Pupilloplasty (PPP) centre in Chennai.
What to do with a filing like this
Dr. Agarwal's Health Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Agarwal's Health Care Limited. Read the original for the full detail.